Insights from the 2022 R&D Innovation Survey
In this playbook, we share insights from 33 biopharma executives who reported their experience using these bellwether approaches for the 2022 R&D Innovation Survey conducted by Health Advances and Parexel Biotech. This innovation snapshot shows biotechs adopting new approaches and encountering a variety of roadblocks, but pushing forward to expand their use and deliver faster, more efficient development.
Considered as a whole, findings from the December 2022 R&D Innovation Survey lead us to three top-line insights:
- Regulatory and commercial strategies must be considered earlier.
- Adaptive designs, ECAs and DCTs are growing in importance.
- Biopharma must pursue new ways to increase diversity in clinical trials.